Barclays PLC Has $1.05 Million Stake in Nkarta, Inc. (NASDAQ:NKTX)

Barclays PLC lifted its position in Nkarta, Inc. (NASDAQ:NKTX) by 161.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 232,566 shares of the company’s stock after purchasing an additional 143,608 shares during the quarter. Barclays PLC’s holdings in Nkarta were worth $1,051,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Meeder Asset Management Inc. acquired a new position in shares of Nkarta in the second quarter valued at $26,000. Erste Asset Management GmbH acquired a new position in shares of Nkarta in the third quarter valued at $33,000. GAMMA Investing LLC raised its stake in shares of Nkarta by 110.9% in the third quarter. GAMMA Investing LLC now owns 9,972 shares of the company’s stock valued at $45,000 after purchasing an additional 5,243 shares in the last quarter. Forefront Analytics LLC acquired a new position in shares of Nkarta in the second quarter valued at $70,000. Finally, Intech Investment Management LLC acquired a new position in Nkarta during the third quarter worth $74,000. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Nkarta Stock Down 3.7 %

Shares of NKTX stock opened at $2.32 on Tuesday. The stock has a 50-day moving average price of $2.84 and a 200 day moving average price of $4.51. The firm has a market cap of $163.72 million, a price-to-earnings ratio of -1.23 and a beta of 0.82. Nkarta, Inc. has a 12 month low of $2.08 and a 12 month high of $16.24.

Analysts Set New Price Targets

A number of research firms have recently issued reports on NKTX. Rodman & Renshaw initiated coverage on shares of Nkarta in a research note on Wednesday, October 9th. They issued a “buy” rating and a $14.00 target price for the company. Needham & Company LLC cut their price objective on Nkarta from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, November 8th. Mizuho decreased their target price on Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a report on Thursday, November 21st. HC Wainwright lowered their target price on Nkarta from $22.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, November 11th. Finally, RODMAN&RENSHAW upgraded Nkarta to a “strong-buy” rating in a research note on Wednesday, October 9th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $15.00.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.